Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline
10 janv. 2022 08h00 HE
|
Surrozen, Inc.
-Initiation of Phase 1 clinical trials of SZN-1326 and SZN-043 expected in third quarter 2022 -Acceleration of preclinical programs includes nomination of lead candidate SZN-413 for retinopathies and...
Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference
05 janv. 2022 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the...
Surrozen Reports Third Quarter 2021 Financial Results
15 nov. 2021 16h00 HE
|
Surrozen, Inc.
Product Candidates SZN-1326 and SZN-043 Advance Toward Initiation of Clinical Studies in 2022 Expanding and Advancing Discovery Stage Pipeline in Multiple Disease Settings SOUTH SAN FRANCISCO,...
Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
15 nov. 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference
15 nov. 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (NASDAQ: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference
05 nov. 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc., (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week
05 oct. 2021 16h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair...
Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources
23 sept. 2021 08h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...
Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration
11 août 2021 17h30 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen”), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and...
Surrozen to Present at Canaccord Genuity’s 41st Annual Growth Conference
05 août 2021 08h00 HE
|
Surrozen, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt...